BRIEF—VBL opens Israel's first commercial-scale gene therapy manufacturing unit

Vascular Biogenics, a cancer-focused biopharma operating under the name of VBL Therapeutics, has announced the opening of its new gene therapy manufacturing plant in Modiin, Israel.

This plant will be the commercial facility for production of the drugmaker’s lead product candidate, ofranergene obadenovec (VB-111), if approved. VB-111 is currently being studied in a pivotal trial in recurrent glioblastoma (rGBM).

The facility, where VBL’s headquarters will also be based, is the first commercial-scale gene therapy manufacturing unit in Israel and currently one of the largest gene therapy designated ones in the world.